Newsfeeds - Spark Newswire

1 minute read

SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $115

Today, 8:01 PM

SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $112 to $115.

BMRN

1 minute read

BioMarin Says Average Net Price Per Patient Per Year Is Estimated At $240,000 For Voxzogo, Says US Wholesale Acquisition Cost, Or List Price, Per Vial Is $899 For Voxzogo

By Bill Haddad

Today, 8:01 PM

-Reuters

BMRN

1 minute read

FDA Conditionally Approves Biomarin’s Dwarfism Drug

By Vandana Singh

Today, 8:01 PM

The FDA has approved BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) Voxzogo (vosoritide) for Injection for achondroplasia. The approval comes for achondroplasia patients five…

BMRN

1 minute read

FDA Approves BioMarin’s Vosoritide For Children With Most Common Form Of Dwarfism

By Benzinga Newsdesk

Today, 8:01 PM

https://www.prnewswire.com/news-releases/fda-approves-first-drug-to-improve-growth-in-children-with-most-common-form-of-dwarfism-301429137.html

BMRN

2 minute read

Entos, BioMarin Report Deal For Product Candidates Incorporating Entos’ Fusogenix Drug Delivery Platform

By Benzinga Newsdesk

Today, 8:01 PM

-- Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseases EDMONTON, AB, Nov. 15, 2021 /PRNewswire/ - Entos Pharmaceuticals, Inc. (Entos), a

BMRN

1 minute read

SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $112

By Benzinga Newsdesk

Today, 8:01 PM

SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $108 to $112.

BMRN

4 minute read

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

By Shanthi Rexaline

Today, 8:01 PM

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

5 minute read

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates

By Shanthi Rexaline

Today, 8:01 PM

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.

AADI